Moderna-Merck personalized mRNA cancer vaccine cuts melanoma recurrence or death by 42% in Phase 3
The personalized mRNA vaccine developed with Merck reduced the risk of melanoma recurrence or death by 42% in a Phase 3 trial, data released early at ESMO 2026
STAT · +14 outlets
FDA approves Moderna's mRNA seasonal flu vaccine
The approval marks the first mRNA-based seasonal influenza vaccine cleared by US regulators.
BioPharma Dive · +13 outlets
FDA approves first targeted RAS inhibitor for metastatic pancreatic cancer
The approval is the first for a drug targeting RAS mutations, long considered undruggable, in advanced pancreatic cancer.
https://streamlinefeed.co.ke/ · +13 outlets
FDA approves GSK's functional cure for hepatitis B
GSK's therapy becomes a rare functional cure approval for chronic hepatitis B infection.
Drug Discovery News · +14 outlets
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
The death renews debate over what safety bar should apply to CAR-T therapies being tested for autoimmune conditions.
STAT · +14 outlets
Tango Therapeutics reports 82% tumor response rate for pancreatic cancer combo therapy
Tango's vopimetostat combination with Revolution Medicines' rasongue showed striking responses in a certain type of advanced pancreatic cancer at ESMO.
STAT · +14 outlets
Treasury proposes restrictions on US investment in Chinese biotech, licensing deals still allowed
The proposal would limit US capital flows into Chinese biotechs while preserving licensing arrangements, drawing pharma reaction.
STAT · +14 outlets
Novartis MS treatment remibrutinib cuts relapse rates by a third in pivotal trials
The oral BTK inhibitor reduced relapses versus a standard treatment, positioning it in a competitive multiple sclerosis market.
STAT · +3 outlets
Most cancer drugs approved by European regulators lack high clinical benefit, analysis finds
A new analysis found most new cancer medicines approved in Europe over a four-year period offered no high clinical benefit.
STAT · +14 outlets
AI drug firm Pathos raises $237M at $3B valuation with BMS and Tempus deal
The financing combines a large Tempus dataset, Pathos AI analysis, and Bristol Myers Squibb drug development.
STAT · +3 outlets
Protein degrader specialist Lycia Therapeutics prices $318M IPO
The upsized offering will fund three protein-degrading medicines for allergic and autoimmune conditions including Graves' disease.
Biopharmadive · +4 outlets
Ultomiris wins accelerated FDA approval for IgA nephropathy
The approval followed a trial showing a 43% greater drop in urine protein for the AstraZeneca rare disease drug.
Medical Daily · +14 outlets
Biotech stocks surge as investors weigh how to play drug innovation boom
A strong year for RNAi developers is helping drive a broad rally in biotech shares.
CNBC · +5 outlets
FDA approves subcutaneous Skyrizi for Crohn's disease induction
The approval adds a subcutaneous induction option for AbbVie's Skyrizi in Crohn's disease.
The Clinical Trial Vanguard · +14 outlets
FDA launches neuroscience innovation program with initial focus on Alzheimer's prevention
The new FDA program aims to accelerate neuroscience drug development, starting with Alzheimer's prevention.
BioBuzz · +10 outlets
Star Therapeutics adds $200M after Electra and Vega spinout exits
Following exits for subsidiaries Electra and Vega, Star is raising new funds to pursue a fresh drug prospect.
Biopharmadive · +4 outlets
State officials scramble to implement Medicaid work requirements
State Medicaid directors met behind closed doors to work out how to carry out sweeping new federal work requirements.
STAT
MDMA-assisted therapy could get FDA approval as soon as January, advocate says
An advocate said the psychedelic-assisted therapy for PTSD could secure US approval early next year.
New York Post